Immunoexpression of bone morphogenetic protein-2 (BMP-2), BMP receptor type IA, and BMP receptor type II in metastatic and non-metastatic lower lip squamous cell carcinoma
Immunoexpression of bone morphogenetic protein-2 (BMP-2), BMP receptor type IA, and BMP receptor type II in metastatic and non-metastatic lower lip squamous cell carcinoma
复制标题
DOI：
10.1111/j.1600-0714.2010.00974.x
复制
发表时间：
2011-02-01
影响因子：
3.3
通讯作者：
Pinto, Leao P.
中科院分区：
文献类型：
--
作者：
de Carvalho, Cyntia H. P.;Nonaka, Cassiano F. W.;Pinto, Leao P.
目的：探讨骨形态发生蛋白-2（BMP-2）、BMPR-IA和BMPR-II在转移性和非转移性下唇鳞状细胞癌（LLSCC）中的表达。根据以下参数评价阳性细胞的百分比：评分1（0-50%的细胞染色）、评分2（51-75%的细胞染色）和评分3（> 75%的细胞染色）。免疫染色强度根据以下评分进行评价：1分（无或弱表达）和2分（强表达）。结果：就阳性细胞百分比而言，大多数有和无转移的肿瘤的BMP-2（P = 0.655）和BMPR-IA（P = 0.655）均为3分。对于BMPR-II，与非转移性肿瘤相比，转移性肿瘤表现出更高的阳性细胞百分比（P = 0.049）。关于免疫染色强度，大多数有和无转移的LLSCC显示BMP-2评分为2（P = 1.000），BMPR-II评分为1（P = 1.000）。对于BMPR-IA，大多数转移性肿瘤的评分为2，而大多数非转移性肿瘤的评分为1（P < 0.001）。BMPR-IA的高表达与LLSCC的临床分期（P < 0.001）和恶性程度（P = 0.028）有关。结论：LLSCC的发生可能与BMP-2信号通路的紊乱有关，BMPR-IA的高表达可能是LLSCC发生转移的一个指标。
Background:The aim of this study was to evaluate the expression of bone morphogenetic protein-2 (BMP-2), BMPR-IA, and BMPR-II in metastatic and non-metastatic lower lip squamous cell carcinoma (LLSCC).Methods:Twenty LLSCC with regional nodal metastasis and 20 LLSCC without metastasis were selected for analysis of the immunoexpression of BMP-2, BMPR-IA, and BMPR-II. The percentage of positive cells was evaluated according to the following parameters: score 1 (staining in 0-50% of cells), score 2 (staining in 51-75% of cells), and score 3 (staining in > 75% of cells). Immunostaining intensity was evaluated according to the following scores: score 1 (absent or weak expression) and score 2 (strong expression).Results:Regarding the percentage of positive cells, most tumors with and without metastasis showed score 3 for both BMP-2 (P = 0.655) and BMPR-IA (P = 0.655). For BMPR-II, metastatic tumors exhibited higher percentage of positive cells in comparison with non-metastatic tumors (P = 0.049). With respect to immunostaining intensity, most LLSCCs with and without metastasis showed score 2 for BMP-2 (P = 1.000) and score 1 for BMPR-II (P = 1.000). For BMPR-IA, most metastatic tumors presented score 2, whereas most non-metastatic tumors showed score 1 (P < 0.001). Strong expression of BMPR-IA showed a statistically significant association with advanced clinical staging (P < 0.001) and high score of malignancy (P = 0.028).Conclusions:The results of this study suggest that disturbances in the BMP-2 signaling pathway may be involved in the development of LLSCC and that the strong expression of BMPR-IA might be indicative of the development of metastasis in these lesions.